Ambrx Biopharma (NYSE:AMAM) Trading 3.6% Higher

Ambrx Biopharma Inc. (NYSE:AMAMGet Rating)’s stock price traded up 3.6% on Friday . The stock traded as high as $2.02 and last traded at $1.99. 163,413 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 964,432 shares. The stock had previously closed at $1.92.

Wall Street Analyst Weigh In

Separately, Robert W. Baird cut their price objective on shares of Ambrx Biopharma from $8.00 to $4.00 in a research report on Wednesday, October 19th.

Ambrx Biopharma Stock Performance

The company’s 50 day simple moving average is $1.53 and its 200 day simple moving average is $1.65.

Hedge Funds Weigh In On Ambrx Biopharma

Large investors have recently bought and sold shares of the stock. FMR LLC increased its stake in Ambrx Biopharma by 0.8% during the 2nd quarter. FMR LLC now owns 3,857,679 shares of the company’s stock valued at $10,223,000 after buying an additional 32,320 shares during the period. Renaissance Technologies LLC increased its stake in Ambrx Biopharma by 91.5% during the 1st quarter. Renaissance Technologies LLC now owns 22,600 shares of the company’s stock valued at $93,000 after buying an additional 10,800 shares during the period. Finally, Royal Bank of Canada acquired a new position in Ambrx Biopharma during the 3rd quarter valued at about $46,000. Institutional investors and hedge funds own 43.14% of the company’s stock.

Ambrx Biopharma Company Profile

(Get Rating)

Ambrx Biopharma Inc, a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer.

Further Reading

Receive News & Ratings for Ambrx Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambrx Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.